Our Science
Pipeline
Innovative Science: Targeting Severe, Rare Conditions
SCYNEXIS is expanding its pipeline with focus on severe rare diseases with high unmet medical need.
Our lead program, SCY‑770, is being developed for autosomal dominant polycystic kidney disease (ADPKD), with the potential to expand into other indications where AMPK activation could provide a meaningful advancement in treatment, such as adrenoleukodystrophy (ADL).
And, our differentiated portfolio of triterpenoid antifungal candidates, with our second generation fungerp SCY-247 targeting serious and difficult‑to‑treat infections.
Learn more about our pipeline and how we are advancing science to improve patient outcomes.
SCYNEXIS Pipeline
Lead program focused on ADPKD
| Preclinical | Phase 1 | Phase 2 | Phase 3 | ||
|---|---|---|---|---|---|
| PXL-770 | Autosomal Dominant Polycystic Kidney Sisease (ADPKD) | ||||
| SCY-247 | Treatment and Prevention of Invasive Fungal Infections | ||||
| Fungerp analogs | Treatment of resistant fungi with novel structural analogs | ||||
|
VVC and Recurrent VVC |
|
|||
GSK has an exclusive license for the development and commercialization of ibrexafungerp for all indications globally, except in the greater China region and certain other countries.
Our Science
Learn more about our commitment to changing the trajectory of severe rare diseases
Learn MoreOur data
Learn more about our commitment to changing the trajectory of severe rare diseases
Learn More